跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
林 鵬展
教授
腫瘤科
電子郵件
pengchan
mail.ncku.edu
tw
h-index
1439
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2005
2026
每年研究成果
概覽
指紋
網路
專案
(1)
研究成果
(99)
類似的個人檔案
(6)
指紋
查看啟用 Peng-Chan Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
100%
Malignant Neoplasm
65%
Neoplasm
27%
Metastatic Colorectal Cancer
26%
Diseases
23%
Overall Survival
21%
Chemotherapy
21%
Oxaliplatin
18%
UFT
17%
Rituximab
17%
Cancer Survival
17%
microRNA
17%
Tumor Growth
13%
Cisplatin
13%
Cancer Recurrence
11%
Carcinogenesis
11%
Calcium Ion
10%
Phosphatidylinositol 3 Kinase
10%
Bloodstream Infection
8%
Lung Disease
8%
Fluorouracil
8%
Circulating Tumor DNA
8%
Y Box Binding Protein 1
8%
Paclitaxel
8%
First-Line Chemotherapy
8%
Docetaxel
8%
Hepatitis B
8%
Taxane
8%
Anthracycline
8%
Folinic Acid
8%
Interleukin 20
8%
Cyclin Dependent Kinase 1
8%
Tetraspanin
8%
Non Small Cell Lung Cancer
8%
Immune Checkpoint Inhibitor
8%
Capecitabine
8%
Scatter Factor Receptor
8%
Vinorelbine
8%
Endometrium Cancer
8%
Cetuximab
8%
Ramucirumab
8%
Lamivudine
8%
Postmarketing Surveillance
8%
Irinotecan
8%
Gamma Urogastrone
8%
Digestive System Cancer
8%
Neuropathy
8%
Metastatic Breast Cancer
8%
Oxaliplatin-Induced Peripheral Neuropathy
8%
Tumor Invasion
8%
Medicine and Dentistry
Colorectal Carcinoma
62%
Germ Cell
20%
Symptomatic Treatment
17%
Uterine Cancer
17%
Gamma Urogastrone
17%
Epidermal Growth Factor Receptor 2
17%
DNA Mismatch Repair
16%
Neoplasm
15%
Metastatic Carcinoma
15%
Diseases
12%
Tumor Progression
10%
Colon Carcinoma
10%
Next Generation Sequencing
9%
Hereditary Nonpolyposis Colorectal Cancer
9%
Cell-Free DNA
8%
Contralateral
8%
Bullous Pemphigoid
8%
False Positive Result
8%
Autophagy
8%
Calcium Ion
8%
Rituximab
8%
Autologous Hematopoietic Stem Cell Transplantation
8%
Tumor Immunity
8%
Tetraspanin
8%
Haemophilia A
8%
Lung Cancer Survival
8%
Phosphoinositide 3-Kinase
8%
Chronic Obstructive Pulmonary Disease
8%
Enzyme Active Site
8%
Scatter Factor Receptor
8%
Protein Expression
8%
Stoma
8%
Total Mesorectal Excision
8%
Mismatch Repair Protein
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Liver Tumor
8%
BRCA Mutation
8%
Ramucirumab
8%
Paraptosis
8%
Wheat Germ Agglutinin
8%
Chelation Therapy
8%
Gastrointestinal Cancer
8%
Assessment of Humans
8%
Medical Oncology
8%
Urgent Care
8%
Propensity Score Matching
8%
Breast Cancer
8%
Dyspnea
8%
Aprepitant
8%
Tumor Recurrence
8%
Keyphrases
Stage III Colorectal Cancer
17%
Variant Impact
17%
Susceptibility Variants
17%
Germline Susceptibility
17%
Colorectal Cancer Patients
11%
Tumorigenesis
10%
Cancer Types
9%
Allele Discrimination
8%
Therapeutic Strategies
8%
Asian Breast Cancer
8%
Contralateral Breast Cancer
8%
Polio Vaccine
8%
Tegafur-uracil
8%
Clinical Outcomes
8%
Weekly Docetaxel
8%
Locally Advanced Gastric Cancer
8%
First-line Chemotherapy
8%
Peripheral Blood Progenitor Cells
8%
Cancer Gene Panel
8%
Weekly Cisplatin
8%
Virus Reactivation
8%
Clinical Treatment
8%
Deficient Mismatch Repair (dMMR)
8%
Rituximab Therapy
8%
Mutation Impact
8%
Oxaliplatin-based Chemotherapy
8%
Adjuvant Capecitabine
8%
Cost Comparison
8%
Stage III-IV
8%
MiR-338
8%
MiR-139
8%
Colorectal Cancer Recurrence
8%
Cingulin
8%
CSF1R Gene
8%
Immune Checkpoint Inhibitors
8%
Differential Outcomes
8%
Membrane Protein Expression
8%
Tetraspanin CD151
8%
Mutational Signatures
8%
Lung Cancer Survival
8%
Anaphylactic Reaction
8%
Metastasis Cancer
8%
Insulin-like Growth Factor 1 Receptor (IGF1R)
8%
Single Surgeon Experience
8%
Recepteur D'origine Nantais
8%
Patients with Colorectal Cancer
8%
MET Receptor
8%
Chemoradiation
8%
Transanal Total Mesorectal Excision (taTME)
8%
Afterlife
8%
